Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

540
This protocol provides a method for the systematic global optimization of genetically encoded biosensors through automation-assisted genetic library generation and assessment. This is coupled with design-of-experiment methodologies to streamline experimentation and enable the selection of genetic components to tune biosensors to specific design outcomes.
540
Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

3.4K
Access to decentralized, low-cost, and high-capacity diagnostics that can be deployed into the community for decentralized testing is critical for combating global health crises. This manuscript describes how to build paper-based diagnostics for viral RNA sequences that can be detected with a portable optical...
3.4K
Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

3.6K
Field-effect biosensing (FEB) is a label-free technique for detecting biomolecular interactions. It measures the electric current through the graphene biosensor to which the binding targets are immobilized. The FEB technology was used to evaluate biomolecular interactions between Hsp90 and Cdc37 and a strong interaction between the two proteins was...
3.6K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

5.4K
This study aimed to present a strategy for identifying drug-peptide interactions. The strategy involves the biopanning of drug-recognizing short peptides based on a quartz-crystal microbalance (QCM) biosensor, followed by bioinformatics analysis for quantitatively assessing the information obtained for the drug recognition and annotation of the drug-binding sites on...
5.4K
Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology07:07

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology

10.0K
The synthesis of asymmetric species of ferrocene is challenging using solution techniques. This report focuses on the methods carried out to produce a ferrocene-biotin bioconjugate using facile and clean reactions accomplished via solid-phase synthesis. Incorporation of a thiolate moiety is shown to impart the ability for immobilization on gold...
10.0K
BioMEMS and Cellular Biology: Perspectives and Applications16:30

BioMEMS and Cellular Biology: Perspectives and Applications

10.1K
The ability to culture cells has revolutionized hypothesis testing in basic cell and molecular biology research. It has become a standard methodology in ...
10.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.

JCI insight·2026
Same author

TEG ® 6s Heparin Neutralization Cartridge for Hemostatic Assessment of Patients Undergoing Cardiovascular Surgery.

Anesthesiology·2025
Same author

Machine Learning Predicts Bleeding Risk in Atrial Fibrillation Patients on Direct Oral Anticoagulant.

The American journal of cardiology·2025
Same author

Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.

The journal of allergy and clinical immunology. In practice·2024
Same author

Reassessing the role of aspirin in patients with coronary artery disease.

Expert opinion on pharmacotherapy·2024
Same author

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.

Kardiologia polska·2024

相关实验视频

Updated: Jan 6, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

540

克洛皮多格雷尔充满了eptifibatide以阻止血小板的活性:克洛皮多格雷尔充满了eptifibatide以阻止血小板的活性 (CLEAR PLATELETS) 研究的结果.

Paul A Gurbel1, Kevin P Bliden, Kazi A Zaman

  • 1Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org

Circulation
|March 2, 2005
PubMed
概括
此摘要是机器生成的。

与高剂量克洛皮多格雷尔 (600毫克) 结合的埃普蒂菲巴提德显著增强了血小板抑制,并减少了选择性冠状动脉支架期间的心肌损伤,与单独使用克洛皮多格雷尔相比. 更高的克洛皮多格雷尔剂量 (600毫克) 比标准剂量 (300毫克) 更有效.

更多相关视频

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

3.4K
Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

3.6K

相关实验视频

Last Updated: Jan 6, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

540
Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

3.4K
Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

3.6K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 血小板生物学 血小板生物学

背景情况:

  • 在选择性冠状动脉支架中,用克洛皮多格雷尔进行预治疗并不常见.
  • 关于300毫克克洛皮多格雷尔加载剂量与600毫克克洛皮多格雷尔加载剂量的药理动力学数据有限.
  • 对于eptifibatide与这些克洛皮多格雷尔治疗方案的比较疗效尚不清楚.

研究的目的:

  • 为了比较300毫克和600毫克克洛皮多格雷尔充满剂量的抗血小板作用.
  • 评估eptifibatide在接受选择性冠状动脉支架的患者的额外益处.
  • 评估对血小板活性和心脏标记物释放的影响.

主要方法:

  • 一个2x2因子研究设计 (n=120) 涉及300毫克或600毫克克洛皮多格勒与或没有eptifibatide.
  • 克洛皮多格雷尔在支架插入后立即使用.
  • 血小板反应性通过聚合计和流动细胞计评估,使用5微摩尔/升的ADP诱导聚合.

主要成果:

  • 在3,8和18-24小时服用600毫克克洛皮多格雷尔后,eptifibatide显著增加了至少两倍的血小板抑制 (P<0.001).
  • 在所有时间点 (P<0.001) 中,600毫克克洛皮多格勒表现出较高的血小板抑制,而不是300毫克克洛皮多格勒没有eptifibatide.
  • 糖蛋白IIb/IIIa (GPIIb/IIIa) 阻塞与心脏标记物释放的减少有关,而eptifibatide显示出GPIIb/IIIa表达的最大抑制 (P<0.05).

结论:

  • 在没有预治疗的选择性支架中,GPIIb/IIIa抑制剂与高剂量的皮多格勒比单独的皮多格勒提供了优越的血小板抑制和较少的心肌缩.
  • 如果没有GPIIb/IIIa抑制剂,600毫克克洛皮多格雷尔比300毫克更有效.
  • 需要进行更大规模的临床试验来证实这些发现.